Abstract:Dysregulated bile acid (BA)/lipid metabolism and gut bacteria dysbiosis are tightly associated with the development of obesity and non-alcoholic fatty liver disease (NAFLD). The orphan nuclear receptor, Small Heterodimer Partner (SHP/NR0B2), is a key regulator of BA/lipid metabolism, and its gene-regulating function is markedly enhanced by phosphorylation at Thr-58 mediated by a gut hormone, fibroblast growth factor-15/19 (FGF15/19). To investigate the role of this phosphorylation in whole-body energy metabolism, we generated transgenic SHP-T58A knock-in mice. Compared with wild-type (WT) mice, the phosphorylation-defective SHP-T58A mice gained weight more rapidly with decreased energy expenditure and increased lipid/BA levels. This obesity-prone phenotype was associated with the upregulation of lipid/BA synthesis genes and downregulation of lipophagy/β-oxidation genes. Mechanistically, defective SHP phosphorylation selectively impaired its interaction with LRH-1, resulting in de-repression of SHP/LRH-1 target BA/lipid synthesis genes. Remarkably, BA composition and selective gut bacteria which are known to impact obesity, were also altered in these mice. Upon feeding a high-fat diet, fatty liver developed more severely in SHP-T58A mice compared to WT mice. Treatment with antibiotics substantially improved the fatty liver phenotypes in both groups but had greater effects in the T58A mice so that the difference between the groups was largely eliminated. These results demonstrate that defective phosphorylation at a single nuclear receptor residue can impact whole-body energy metabolism by altering BA/lipid metabolism and gut bacteria, promoting complex metabolic disorders like NAFLD. Since posttranslational modifications generally act in gene- and context-specific manners, the FGF15/19-SHP phosphorylation axis may allow more targeted therapy for NAFLD.

Targeting orphan nuclear receptor SHP in the treatment of metabolic diseases

Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP

New Insights into Orphan Nuclear Receptor SHP in Liver Cancer

The Metabolic Regulator Small Heterodimer Partner Contributes to the Glucose and Lipid Homeostasis Abnormalities Induced by Hepatitis C Virus Infection

The Orphan Nuclear Receptor 4A1: A Potential New Therapeutic Target for Metabolic Diseases

Therapeutic Potential of Targeting SHP2 in Human Developmental Disorders and Cancers

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK/NF-κB pathway-mediated renal inflammation

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Targeting SHP2 as a therapeutic strategy for inflammatory diseases

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders

Advances in SHP2 Tunnel Allosteric Inhibitors and Bifunctional Molecules

Structural and Biochemical Basis for Selective Repression of the Orphan Nuclear Receptor Liver Receptor Homolog 1 by Small Heterodimer Partner

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds

Disrupting Phosphatase SHP2 in Macrophages Protects Mice from High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance by Elevating IL-18 Levels

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

The Cell-Specific Role of SHP2 in Regulating Bone Homeostasis and Regeneration Niches

Transgenic mice lacking FGF15/19-SHP phosphorylation display altered bile acids and gut bacteria, promoting nonalcoholic fatty liver disease